Related Experiment Video
Updated: Apr 23, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse
Florence Abravanel1, Sébastien Lhomme1, Lionel Rostaing2
1INSERM, U1043, Centre de Physiopathologie de Toulouse Purpan CHU Toulouse, Hôpital Purpan, Laboratoire de virologie, Centre National de Référence Hépatite E, Institut fédératif de biologie de Purpan.
Abstract:
Twenty-four solid-organ-transplant recipients with chronic hepatitis E virus (HEV) infections were given ribavirin therapy for 3 months. All the patients with protracted fecal HEV shedding during treatment suffered a relapse. Monitoring HEV fecal excretion could be used to determine the optimal duration of ribavirin therapy.
Related Concept Videos
Viral Hepatitis I: Introduction
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Bacterial Gastroenteritis
Drugs for Treatment of Ulcerative Colitis in IBD
Hepatic Encephalopathy
Hepatitis

